Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merus B.V.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years or older
At least one evaluable or measurable lesion according to RECIST v1.1
Patient with advanced metastatic solid tumor with documented NRG1 fusion determined in a qualified local laboratory by molecular profiling using methods such as next generation sequencing \[DNA or RNA\] as routinely performed at CLIA or other similarly-certified laboratories.
Treatment with anticancer medications or investigational drugs within the following intervals before the first administration of MCLA-128:
1. At least 14 days for chemotherapy, targeted small molecule therapy, or radiation therapy OR
2. At least 5 half-lives have passed since discontinuation of the systemic treatment
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
Adequate organ function at the time of initiation of treatment administration
Negative pregnancy test results in women of childbearing potential (defined as women ≤50 years of age or history of amenorrhea for ≤12 months prior to study entry)
Ability to give written, informed consent prior to treatment, with the understanding that the consent may be withdrawn by the patient at any time without prejudice
You may not be if
Any condition that in the opinion of Merus may preclude appropriate use of the investigational medicine
Any untreated, symptomatic central nervous system (CNS) lesion
Presence of an active and uncontrolled infection
Leptomeningeal metastases
Known hypersensitivity to any of the components of MCLA-128 or history of severe hypersensitivity reactions to human or humanized monoclonal antibodies, including therapeutic antibodies
Presence of LVEF \<50% on the screening echocardiogram; or history or presence of any significant cardiovascular disease, including unstable angina or myocardial infarction within 12 months prior to treatment, congestive heart failure (NYHA Class III or IV), or ventricular arrhythmia requiring medication
Presence of any other medical or psychological condition deemed by the Physician to be likely to interfere with a patient's ability to sign informed consent, cooperate or participate in the study, or interfere with the interpretation of the results.
Clareo Health | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
